The major secreted isoenzyme of human prostatic acid phosphatase (PAcP) ( 
INTRODUCTION
Phosphorylation and dephosphorylation is a major mechanism for enzyme regulation in eucaryotic systems (Greengard, 1978; Krebs & Beavo, 1979; Cohen, 1982) . Several oncogene proteins and growth factor receptors have been found to possess protein phosphorylation activity specific for tyrosine residues. Thus tyrosyl protein kinases are believed to be important in normal and malignant growth of cells (Bishop, 1983; Heldin & Westermark, 1984) .
Since the level oftyrosine phosphorylation is apparently important in neoplastic transformation and in normal cell growth control, the relative rate of tyrosine phosphorylation compared with phosphotyrosine dephosphorylation may be an important regulatory mechanism in cell growth control. Although much effort has been directed at characterizing tyrosyl kinases, relatively little is known regarding phosphotyrosine phosphatases and their physiological significance. The observation that dephosphorylation of phosphotyrosine residues occurs directly following the loss of the transformed phenotype in cells transformed by temperature-sensitive mutants of Rous sarcoma virus and Fujinami sarcoma virus (Bishop, 1983; Foulkes, 1983) , following the initial increase in phosphotyrosine residues upon the addition to cells of platelet-derived growth factor, epidermal growth factor (Heldin & Westermark, 1984) and diverse mitogenic agents (Nakamura et al., 1983; Kohno, 1985) , suggest an important physiological role for phosphotyrosine phosphatase in regulation of the growth of normal and transformed cells.
Human prostatic acid phosphatase (PAcP) is composed of a group of acid phosphomonoesterases. The major PAcP isoenzyme (Mr 100000) is a glycoprotein which has previously been shown to hydrolyse phosphomonoesters with optimal activity at pH 4-6 (Yam, 1974; Lin et al., 1983a) . The major isoenzyme has been found to be expressed at a high level in the normal prostate gland and to have repressed expression in prostate tumour tissue (Yam, 1974; Loor et al., 1981) . To determine the physiological function, we purified the major PAcP isoenzyme and tested the enzyme for its phosphotyrosyl protein phosphatase activity. The results support the hypothesis that PAcP may play a role in determining the phosphorylation state of phosphotyrosine-containing proteins.
MATERIALS AND METHODS

Materials
[y-32P]ATP (sp. radioactivity 2900 Ci/mmol) was purchased from New England Nuclear, Boston, MA, U.S.A. Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-ProPhe), p-nitrophenyl phosphate, p-nitrophenol standard solution, O-phosphotyrosine, L(+)-tartaric acid, hydrolysed, partially dephosphorylated casein, protein A-Sepharose CL4B, and NaF were from Sigma Chemical Co., St. Louis, MO, U.S.A. Bio-Rad dye was from Bio-Rad Laboratories, Richmond, CA, U.S.A. Rabbit anti-PAcP antibody was a gift from Dr. C. L. Lee. The catalytic subunit of the cyclic AMP-dependent protein kinase was a gift from Dr. R. Roskoski. All other materials were obtained as previously described (Clinton Purification of prostatic acid phosphatase
The major PAcP isoenzyme with Mr 100000 was purified from human seminal plasma as. we have previously described by using a purification scheme which included (NH4)2SO4 'fMctiohation, concanavalin ASepharose 4B0 afflni-ty/shxromatograph,y, DEAE-cellulose ion exchange chromatography, and Sephadex G-100 and G-150 gel filtrations (Lee et al., 1978; Lin et al., 1983a,b) . The purified PAcP was found to have a single N-terminal protein sequence (Lin et at.,-1983b; Taga et at.; . The--<; purified enzyme was stored at -20°C in 0.1 M-citrate, pH 6.0, where it was stable for several months. The protein concentration was determined by the Bio-Rad dye protein assay with bovine serum albumin as the standard. Purified PAcP was also subjected to gel filtration by h.p.l.c. on a Spherogel-TSK SW 4000 column (Beckman Instruments, Berkeley, CA, U.S.A.) equilibrated with 5 mm-citrate, pH 5.8, containing 0.2 M-NaCl. A 200 ,ul sample of purified PAcP (0.4 mg/ml) was chromatographed on the column at 24°C and fractions were stored at 0 'C. A 3 ,d aliquot of each fraction was removed for the phosphotyrosyl phosphatase assay with phosphoangiotensin as the substrate and for the acid phosphatase determination.
Acid phosphatase determinations
PNPP at 3 mm in 50 mM-citrate, pH 6.0 (final volume 0.4 ml), was used to determine esterase activity. Incubation was performed at 34 'C for the time indicated in the Figure legends. The reaction was terminated by the addition of 2.0 ml of 0.1 M-NaOH. The released p-nitrophenol was measured spectrophotometrically at 410 nm and p-nitrophenol standard solution was used to determine the amount of phosphate released (Lin et al., 1983a) .
Preparation of 32P-labelled phosphoproteins 32P-labelled angiotensin II was prepared by using protein kinase obtained from human serum (Lin et al., 1985) . The phosphorylated angiotensinlI wasrpurified by high voltage paper electrophoresis, eluted from the paper with water, lyophilized and stored at -20 'C.
32P-labelled anti-pp60src IgG and casein were phosphorylated on tyrosine residues by partially purified pp60src protein in immunocomplexes as previously described (Clinton et al., 1982) . After the kinase reaction the 32P-labelled proteins were precipitated with trichloroacetic acid and washed with acetone. The washed pellet was dialysed against 50 mM-citrate, pH 6.0, and stored at -20°C.
32P-labelled casein, phosphorylated on seine residues, was prepared by using the catalytic subunit of the cyclic AMP-dependent protein kinase (Roskoski, 1983) . The phosphorylation reaction was carried out at 34°C for 30 min. The reaction was terminated and unincorporated radioisotope was removed by precipitating the protein with trichloroacetic acid and washing the pelleted protein with acetone as described above.
To characterize the above products, SDS/polyacrylamide-gel electrophoresis (Laemmli, 1970) The assay was carried out in a reaction volume of 30 ,1 containing 50 mM-citrate, pH 6.0, and 0.024 ,ug of enzyme unless otherwise specified. The reaction was terminated by boiling for 5 min. The incubation time as well as incubation temperature in each assay was adjusted so that less than 25% of the 32P, was released from the phosphoproteins. The released 32P1 was separated from other reaction components by electrophoresis at pH 4.4 for 20 min at 1500 V. The product that comigrated with the 32P, marker was localized by autoradiography, cut from the paper, and quantified by terenkov counting.
Immunoprecipitation of phosphatase activities
Antiserum made in rabbits against purified PAcP was determined to be specific for PAcP by the solid-phase immunofluorescence assay (Lee et al., 1978; Chu et al., 1982) . The titre of specific IgG prepared from antiserum as previously described (Lee et al., 1978) was determined by titrating different dilutions of IgG with 250 ng of purified enzyme. A 50% binding of IgG to PAcP was chosen for comparing inhibition of the two phosphatase activities. For the immunoprecipitations, the purified enzyme was incubated at 4°C for 1 h in 50 mM-citrate, pH 6.0, with the IgG fraction. Protein A-Sepharose 4B at an equivalent concentration to the IgG was added for a 30 min incubation. After centrifugation at 4°C, the supernatant was removed. PNPP acid phosphatase and phosphotyrosyl phosphatase activities in the supernatant were determined.
RESULTS
Prostatic acid phosphatase functions as a phosphotyrosyl protein phosphatase
The purpose of our study was to test whether the major isoenzyme of PAcP, an enzyme previously characterized to hydrolyse PNPP at acid pH, can function to hydrolyse phosphomonoesters to tyrosine in proteins. The PAcP used in these studies was purified to homogeneity from seminal plasma according to a procedure we have used previously (Lin et al., 1983a,b (Lin et al., 1983b) .
One phosphotyrosine-containing substrate we tested for dephosphorylation by PAcP was phosphorylated angiotensin II. Angiotensin II has been found to be phosphorylated by several tyrosyl kinases (Wong & Goldberg, 1983; Lin et al., 1985) and since it contains tyrosine, but not serine or threonine which are the other major amino acids phosphorylated by the known protein kinases, angiotensin II provides a substrate which can be exclusively phosphorylated in tyrosine. Fig. 1 (Fig. 2) . Although the concentration of phosphorylated angiotensin II was in the nanomolar range (0.5 nM), the dephosphorylation reaction was time-dependent ( Fig. 1) and enzyme-concentration-dependent (Fig. 2) . These results obtained using highly purified enzyme and substrate indicate that PAcP has phosphotyrosyl phosphatase activity.
To demonstrate the copurification of PAcP and the phosphotyrosyl phosphatase, the enzyme activities were measured after h.p.l.c. gel filtration of purified PAcP. As shown in Fig. 3 , a single protein peak contained both the phosphotyrosyl phosphatase and the PNPP acid phosphatase activities.
Vol. 235 Effects of inhibitors on the phosphatase activities To characterize further and compare both phosphatase activities, the effects of different inhibitors on PNPP hydrolysis and on phosphoangiotensin II dephosphorylation by PAcP were investigated (Table 1) . PNPP, a substrate for PAcP, inhibited the dephosphorylation of 32P-labelled angiotensin II by 93 %. Tartrate, a relatively specific inhibitor ofPAcP but not ofalkaline phosphatases or of several other acid phosphatases (Fishman & Lerner, 1953; Yam, 1974) The purified PAcP was preincubated at 56°C in 50 mm-itrate, pH 6.0. At the indicated time intervals, aliquots were removed and measured for acid phosphatase activity (0) with PNPP or for phosphotyrosyl phosphatase activity (0) with phosphoangiotensin II as substrate.
at increasing inhibitor (phosphoangiotensin II) concentration the Km of the enzyme for PNPP is increased whereas the Vmax. remains unchanged. Furthermore, the apparent Ki of about 0.9 x 10-9 M is nearly equal to the apparent Km (1.1 x 10-9 M) for phosphoangiotensin II (see Table 3 ). Therefore, phosphoangiotensin II is a competitive inhibitor of the PNPP acid phosphatase. Temperature effects on phosphatase activities To explore further the phosphotyrosyl phosphatase activity and the PNPP acid phosphatase activity associated with PAcP, their thermostabilities were compared. As shown in Fig. 5 , the two enzymic activities exhibited the same thermal sensitivities at 56 'C. After incubation at 56 'C for 30 min, about 30% of the activities remained for both acid phosphatase and for phosphotyrosyl phosphatase. Effects of anti-PAcP antibody on phosphatase activities
Immunoassays have been developed to distinguish prostate-specific acid phosphatase (PAcP) from other acid phosphatases (Henderson & Nealson, 1981; Chu et al., 1982 ). An antibody made to the purified PAcP and a control, preimmune, serum were tested for their reactivities toward the phosphotyrosyl phosphatase and the PNPP acid phosphatase activities. The antibody was used at a concentration previously determined to cause about 50% loss of PNPP phosphatase activity. After absorption with the specific antibody and precipitation of the immune complex with protein A-Sepharose, the enzyme remaining in the supernatant was assayed for (mol/min per mg)
Phosphoangiotensin II 1.1 x 10-9 1.5 x 10-10 Phosphotyrosine-IgG 1.7 x 10-9 8.2 x 10-11 Phosphotyrosine-casein 9.6 x 10-10 5.6 x 10-11 Phosphoserine-casein 6.3 32P-labelled angiotensin II was used as the substrate with 0.3 nM-PAcP. The assay was for 1 min at 24°C under conditions where the rate of dephosphorylation was linear with all substrate concentrations. The Km was calculated to be 1.1 x 10-9 M by the method of Lineweaver & Burk (1934) .
PNPP acid phosphatase as well as for phosphotyrosyl phosphatase activity. As shown in Table 2 , about 60% of both the phosphotyrosyl phosphatase activity and the PNPP acid phosphatase activity was lost following the reaction with antibodies to PAcP. (Fig. 6) . Using 32P-labelled anti-pp60src IgG as the substrate, a Km of 1.7 x 10-9 M, which was similar to that for phosphoangiotensin II, was obtained (Table 3) . To compare the affinity of PAcP for phosphotyrosine with that for the major phosphoamino acid in cells, phosphoserine, the apparent Km values for the two were determined. As shown in Table 3 , the apparent Km value for casein containing phosphotyrosine was about 50-fold less than that for casein which contained phosphoserine.
The kinetic data obtained for several substrates revealed other properties of the enzyme. The enzyme was found to have a lower Km for protein substrates than for small phosphate-containing compounds. The Km values determined for PNPP and for free O-phosphotyrosine were found to be more than five orders of magnitude higher than for phosphotyrosine proteins (Table 3) . Although PAcP showed a higher affinity for protein substrates, the Vmax. values for PNPP and for phosphotyrosine were greater than for the phosphoproteins (Table 3) .
DISCUSSION
The results of this study demonstrate that the major acid phosphatase from serminal plasma, PAcP, is a phosphotyrosyl protein phosphatase. Several lines of evidence indicate that phosphotyrosyl phosphatase and PNPP phosphatase activities are mediated by the same enzyme. First, the two activities copurified. Second, tartrate, an inhibitor which distinguishes PAcP from several other alkaline and acid phosphatases, and PNPP, a substrate for PAcP, were both efficient inhibitors of the phosphotyrosyl phosphatase activity. Third, both phosphatase activities showed the same sensitivity to inactivation by heat and similar reactivity with antibody to PAcP. Most importantly, phosphoangiotensin II showed competitive inhibition of PNPP dephosphorylation by PAcP. Therefore, we conclude that both enzymes have the same active site.
While this work was in progress, Li et al. (1984) reported that phosphotyrosyl phosphatase activity copurified with the major acid phosphatase of 100000 Da from prostate tissue. The acid phosphatase used in our studies was purified from human semen and may be the secreted form of the enzyme investigated by Li et al. (1984) . In addition to confirming the finding that phosphotyrosyl phosphatase activity copurifies with acid phosphatase from prostate, our study provides evidence that both PNPP and phosphotyrosine dephosphorylation occur at the same active site. We also provide additional kinetic analyses of the phosphotyrosyl phosphatase activity, including Km determinations for phosphotyrosine-and phosphoserine-containing proteins.
PAcP showed substrate selectivity that may be of physiological importance. The enzyme showed a very high affinity (Km in the nanomolar range) for phosphotyrosine in different substrates. In fact PAcP has the highest affinity for phosphotyrosine residues in proteins of any phosphotyrosyl phosphatase yet investigated (Foulkes, 1983; Lau et al., 1985) . Phosphotyrosine in proteins is present at very low levels in most cells and is the least abundant ofany ofthe acid-stable phosphoamino acids (Hunter & Sefton, 1980) . Therefore, it is expected that a phosphotyrosyl phosphatase which functions in the regulation of phosphotyrosine levels in cells would have an exceptionally high affinity for phosphotyrosine. Moreover, PAcP was also found to have a greater affinity for phosphotyrosine than for phosphoserine in proteins. The Km for proteins which contained exclusively phosphotyrosine, including angiotensin II, IgG, and casein, was about 50-fold lower than for casein which contained only phosphoserine. The finding that the Vmax was about the same for casein which contained either phosphoserine or phosphotyrosine suggests that, once associated with the enzyme, the rate of phosphate hydrolysis was the same when the phosphomonoester was adjacent to a polypeptide. The Vmax. was relatively low when phosphoprotein substrates were used. Kinetic analysis ofPAcP with authentic cellular phosphotyrosinecontaining substrates in their native state may result in a higher Vmax.. This can be tested only when the endogeneous substrates have been identified. Although the Vmax. is low, the concentration of PAcP is very high in prostate tissue and appears to be themajor phosphotyrosyl phosphatase in prostate tissue (Li et al., 1984) .
There are some puzzling aspects of the kinetics of phosphotyrosine dephosphorylation by PAcP. When the substratephosphoangiotensinwasatlowerconcentrations than the enzyme (0.5 nm compared with 1.6 nm ofenzyme protein) and less than the Km of 1.1 nm, the reaction rate was linear for up to 3.0 min (Fig. 1) . Moreover, the rate was proportional to the enzyme concentration up to 16.7 nm (Fig. 2 ) even though the substrate was only at 0.6 nm. One possible explanation for linear kinetics under these conditions is because of the slow rate of release of the enzyme-product complex. Li et al. (1984) also observed a slow phosphoprotein substrate turnover rate using a tartrate-sensitive acid phosphatase purified from prostate tissue. They observed only about 40% dephosphorylation of the substrate (0.4 nM-substrate and 1.24 nm-enzyme) in a 1 h reaction at 37 'C. Another possible explanation which we cannot rule out is that a subpopulation of PAcP, perhaps a modified form, is active as a phosphotyrosyl phosphatase. It is unlikely that there is a minor contaminant of the PAcP which is responsible for the phosphotyrosyl phosphatase activity, since the enzyme was extensively purified and since the phosphotyrosyl phosphatase substrate, phosphoangiotensin, was a competitive inhibitor of PAcP activity.
The very high affinity (Km in nm range) of the substrate we used, phosphoangiotensin II, for PAcP can lead to non-linear double reciprocal plots (see Dixon & Webb, 1979) . However, a linear relationship was obtained in several independent experiments (see Fig. 6 ). Apparently the phosphoangiotensin II concentrations we used were in the linear range of double-reciprocal plotting. The expected kinetics were observed, however, when higher concentrations (3-16 nM) of phosphoangiotensin were used. In this case a curved double-reciprocal plot was obtained (results not shown).
Our finding that PAcP is capable ofdephosphorylating phosphoserine groups in proteins is in contrast with the results of Li et al. (1984) which showed the lack of activity of an acid phosphatase purified from prostate toward phosphoserine. It is possible that the differences observed in activities toward phosphoserine may have been caused by the different substrates used. The casein used in our study was first partially dephosphorylated and then phosphorylated by a serine-specific protein kinase and [y-32P]ATP. However, the a-casein used in the studies of Li et al. (1984) was not apparently first dephosphorylated and may have contained higher amounts of unlabelled phosphoserine. If the level of unlabelled phosphoserine was high enough, measurements ofdephosphorylation by the 32P released may have been, obscured. It is also possible that the secreted form of PAcP used in our study has slightly different biochemical properties than the cellular form of PAcP.
The identification and partial characterization of PAcP as a phosphotyrosyl phosphatase provides a new biochemical tool with which to probe the role of phosphotyrosine residues in cell transformation. There is suggestive evidence that this phosphatase may play a role in the malignant growth of prostate tumours. The major PAcP isoenzyme is reduced by at least 75% in tumour tissue from prostate (Yam, 1974; Loor et al., 1981) . Furthermore, the growth rate of prostate tumour cell lines is inversely correlated with the level of PAcP produced by the cells. If PAcP functions as a phosphotyrosyl phosphatase, then a reduction of its activity should result in an increased level of phosphotyrosine in proteins. Recent studies in our laboratory show that the phosphotyrosine, but not the phosphoserine or phosphothreonine, residues are specifically amplified in prostate tumour cells; moreover, this is associated with repressed levels of PAcP (M.-F. Lin & G. M. Clinton, unpublished work) . The combined data suggest that expression of prostatic acid phosphotyrosyl phosphatase is at least partially responsible for determining the net amount of phosphotyrosine residues in proteins, and possibly the malignant growth of the cells.
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